Significance of the study:
Given that (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment required to treat DM; and (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult β-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.
From research findings to therapeutic opportunity:
This study suggests an MiRNA-based Regenerative therapy for DM. MiRNA-208-3p, by decreasing the expression of its target gene, it may: (1) increase the expression of modulator of lipid homeostasis liver X receptor (LXR)-α; (2) decrease plasma levels of triglyceride and cholesterol; (3) protect against diet-induced weight-gain; and (4) increase insulin-secreting cell mass and function.
Thereby, it may increase insulin sensitivity and leanness. Thus, pharmacological formulations encompassing “MiRNA-208-3p or its activators or MiRNA-208-3p plus any of the known anti-metabolic compounds in use” can be used to treat metabolic disorders, including DM.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How MiRNA-208-3p increases: (1) (LXR)-α expression; (2) and insulin-secreting cell mass and function.
Citation: Boominathan, L., Molecular therapy for Metabolic disorders: MiRNA-208-3p increases (LXR)-α expression, insulin-secreting cell mass and function via down regulation of its target genes, 21/November/2016, 11.04 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com